A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

ClinicalTrials.gov ID: NCT01456325

Public ClinicalTrials.gov record NCT01456325. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in participants with incurable non-small cell lung cancer identified to be Met diagnostic-positive. Participants will be randomized to receive either onartuzumab (MetMAb) or placebo in combination with erlotinib. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Study identification

NCT ID: NCT01456325
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 494 participants

Conditions and interventions

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2011
Primary completion: Dec 31, 2015
Completion: Dec 31, 2015
Last update posted: Nov 1, 2016

2012 – 2016

United States locations

U.S. sites: 56
U.S. states: 22
U.S. cities: 50

Facility	City	State	ZIP	Site status
Not listed	Chandler	Arizona	85224	—
Not listed	Hayward	California	94545	—
Not listed	Modesto	California	95355	—
Not listed	Oakland	California	94611	—
Not listed	Orange	California	92868	—
Not listed	Roseville	California	95661	—
Not listed	Sacramento	California	95817	—
Not listed	Sacramento	California	95825	—
Not listed	San Diego	California	92108	—
Not listed	San Francisco	California	94115	—
Not listed	San Jose	California	95119	—
Not listed	Santa Clara	California	95051	—
Not listed	South San Francisco	California	94080	—
Not listed	Vallejo	California	94589	—
Not listed	Walnut Creek	California	94596	—
Not listed	Boca Raton	Florida	33486	—
Not listed	Clearwater	Florida	33761	—
Not listed	Fort Myers	Florida	33901	—
Not listed	Jacksonville	Florida	32207	—
Not listed	Jacksonville	Florida	32256	—
Not listed	Chicago	Illinois	60637	—
Not listed	Urbana	Illinois	61801	—
Not listed	Bettendorf	Iowa	52722	—
Not listed	Sioux City	Iowa	51101	—
Not listed	Louisville	Kentucky	40207	—
Not listed	Annapolis	Maryland	21401	—
Not listed	Baltimore	Maryland	21201	—
Not listed	Baltimore	Maryland	21231	—
Not listed	Baltimore	Maryland	21237	—
Not listed	Boston	Massachusetts	02114	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Springfield	Massachusetts	01107	—
Not listed	Ann Arbor	Michigan	48106	—
Not listed	Duluth	Minnesota	55805	—
Not listed	St Louis	Missouri	63110	—
Not listed	Omaha	Nebraska	68114	—
Not listed	Reno	Nevada	89502	—
Not listed	Farmington	New Mexico	87401	—
Not listed	Syracuse	New York	13210	—
Not listed	Chapel Hill	North Carolina	27514	—
Not listed	Canton	Ohio	44718	—
Not listed	Cleveland	Ohio	44106	—
Not listed	Columbus	Ohio	43210	—
Not listed	Columbus	Ohio	43219	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Pittsburgh	Pennsylvania	15232	—
Not listed	Charleston	South Carolina	29403	—
Not listed	Columbia	South Carolina	29210	—
Not listed	Chattanooga	Tennessee	37404	—
Not listed	Knoxville	Tennessee	37909	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Dallas	Texas	75390	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Houston	Texas	77030	—
Not listed	Bristol	Virginia	24201	—
Not listed	Roanoke	Virginia	24014	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 157 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01456325, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 1, 2016 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01456325 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →